Form 4: Corbus Pharmaceuticals Director Yong Ben Receives Stock Grant

Director Yong Ben of Corbus Pharmaceuticals Holdings, Inc. was granted 2,783 restricted stock units (RSUs) on May 30, 2024, which will vest in one year.

Summary

• Yong Ben, a director of Corbus Pharmaceuticals Holdings, Inc., filed a Form 4 on June 3, 2024, reporting a transaction.
• On May 30, 2024, Ben was granted 2,783 restricted stock units (RSUs).
• These RSUs will vest 100% on the one-year anniversary of the grant date and will be settled in shares of common stock with a par value of $0.0001.
• Ben also has a Power of Attorney naming Yuval Cohen, Ph.D., Sean Moran, and Meghan Houghton as attorneys-in-fact to handle SEC filings related to Corbus Pharmaceuticals Holdings, Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The grant of RSUs indicates confidence in the company's future performance.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.

Future Outlook

The vesting of the RSUs in one year suggests a continued alignment of the director's interests with the company's performance.

Industry Context

The granting of stock-based compensation is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Madrigal Pharmaceuticals and Viking Therapeutics also utilize stock options and RSUs to incentivize their leadership teams.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates